Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Cantor Fitzgerald
QuintilesIMS
Moodys
US Army
US Department of Justice
Medtronic
Teva
Chubb
Julphar
Boehringer Ingelheim

Generated: August 18, 2017

DrugPatentWatch Database Preview

Allergan Sales Llc Company Profile

« Back to Dashboard

What is the competitive landscape for ALLERGAN SALES LLC, and when can generic versions of ALLERGAN SALES LLC drugs launch?

ALLERGAN SALES LLC has thirty approved drugs.

There are twenty-one US patents protecting ALLERGAN SALES LLC drugs.

There are one hundred and eighty-seven patent family members on ALLERGAN SALES LLC drugs in thirty countries.

Summary for Applicant: Allergan Sales Llc

Patents:21
Tradenames:27
Ingredients:21
NDAs:30
Drug Master File Entries: (click here to view)2
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan Sales Llc
ANDRODERM
testosterone
FILM, EXTENDED RELEASE;TRANSDERMAL020489-001Sep 29, 1995DISCNNoNo► Subscribe► Subscribe► Subscribe
Allergan Sales Llc
KADIAN
morphine sulfate
CAPSULE, EXTENDED RELEASE;ORAL020616-010Jul 9, 2012ABRXYesNo► Subscribe► Subscribe► Subscribe
Allergan Sales Llc
ALORA
estradiol
FILM, EXTENDED RELEASE;TRANSDERMAL020655-001Dec 20, 1996BXRXNoNo► Subscribe► Subscribe► Subscribe
Allergan Sales Llc
CRINONE
progesterone
GEL;VAGINAL020701-002Jul 31, 1997RXYesYes► Subscribe► Subscribe► Subscribe
Allergan Sales Llc
DILACOR XR
diltiazem hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL020092-002May 29, 1992DISCNYesNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Allergan Sales Llc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Allergan Sales Llc
OXYTROL
oxybutynin
FILM, EXTENDED RELEASE;TRANSDERMAL021351-002Feb 26, 2003► Subscribe► Subscribe
Allergan Sales Llc
TRELSTAR
triptorelin pamoate
INJECTABLE;INTRAMUSCULAR020715-001Jun 15, 2000► Subscribe► Subscribe
Allergan Sales Llc
RAPAFLO
silodosin
CAPSULE;ORAL022206-001Oct 8, 2008► Subscribe► Subscribe
Allergan Sales Llc
DILACOR XR
diltiazem hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL020092-001May 29, 1992► Subscribe► Subscribe
Allergan Sales Llc
KADIAN
morphine sulfate
CAPSULE, EXTENDED RELEASE;ORAL020616-001Jul 3, 1996► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for ALLERGAN SALES LLC drugs

Drugname Dosage Strength Tradename Submissiondate
oxybutynin chloride
Gel10%
GELNIQUE
6/19/2014
milnacipran hydrochloride
Tablets12.5 mg, 25 mg, 50 mg, and 100 mg
SAVELLA
1/14/2013
silodosin
Capsules4 mg and 8 mg
RAPAFLO
10/9/2012
oxybutynin
Transdermal System Extended-re3.9 mg/24 hrs
OXYTROL
8/19/2008

Non-Orange Book Patents for Allergan Sales Llc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,652,491Transdermal compositions for anticholinergic agents► Subscribe
7,335,379Transdermal pharmaceutical formulation for minimizing skin residues► Subscribe
6,635,675 Method of treating chronic fatigue syndrome► Subscribe
7,214,381Composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels► Subscribe
8,980,309Transdermal testosterone formulation for minimizing skin residues► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Allergan Sales Llc Drugs

Country Document Number Estimated Expiration
South Korea20050061588► Subscribe
World Intellectual Property Organization (WIPO)03053426► Subscribe
Germany60143477► Subscribe
World Intellectual Property Organization (WIPO)2010129498► Subscribe
Australia2016200825► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Allergan Sales Llc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2013025Lithuania► SubscribePRODUCT NAME: CLINFAMYCINUM + TRETINOINUM; REGISTRATION NO/DATE: LT/1/13/3279/001, 2013 04 26 LT/1/13/3279/002, 2013 04 26 PA1332/043/001 20130323
156Luxembourg► SubscribePRODUCT NAME: LEVONORGESTREL ET ETHINYLESTRADIOL; FIRST REGISTRATION DATE: 20150211
00C/027Belgium► SubscribePRODUCT NAME: ETHINYLESTRADIOLUM / NORETHISTERONI ACETAS; NAT. REGISTRATION NO/DATE: 19 IS 106 F3 20000911; FIRST REGISTRATION: NL RVG 23909 19991124
C0001France► SubscribePRODUCT NAME: ETHINYLESTRADIOL BETADEX CLATHRATE; NAT. REGISTRATION NO/DATE: NL 32343 20060710; FIRST REGISTRATION: NL - RVG 31781 20050804
C/GB02/037United Kingdom► SubscribePRODUCT NAME: TELMISARTAN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/02/213/001 20020419; UK EU/1/02/213/002 20020419; UK EU/1/02/213/003 20020419; UK EU/1/02/214/004 20020419; UK EU/1/02/213/005 20020419; UK EU/1/02/213/006 20020419; UK EU/1/02/213/007 20020419; UK EU/1/02/213/008 20020419; UK EU/1/02/213/009 20020419; UK EU/1/02/213/010 20020419
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Novartis
Express Scripts
McKinsey
Fuji
Chubb
Cerilliant
Mallinckrodt
Medtronic
Farmers Insurance
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot